eli lilly tirzepatide fda approval approves new weight-loss drug Zepbound (tirzepatide) Gets FDA Approval – FDA Approves Eli Lilly’s Zepbound

In the 40-week trial, more patients receiving semaglutide 0.5 mg achieved weight loss of 5 % and 10 % (44 % and 14 %) versus patients receiving dulaglutide 0.75 mg (23 % and 3 %)

Obesity-Focused Label Expansions and Coverage Gains The FDA cleared semaglutide for cardiovascular risk reduction in March 2024, which unlocked Medicare Part D coverage because the drug now treats a covered cardiovascular condition rather than obesity alone

Sun exposure, air pollution, and the metabolic demands of mental and physical work all generate free radicals

Without lifestyle modification protocols, it can be a disappointing experience

Karolina I recently had Dysport injected by NP Kristina, and I could not be happier with the outcome

The downstream improvements in hormones, cycles, and symptoms follow naturally